NuvoAir Aos, a sensor that can track how inhalers are used by people with chronic obstructive pulmonary disease (COPD) or asthma, has been introduced in Europe and is likely to be approved in the US soon. The sensor can be attached to pressurized metered dose inhalers and works with both quick-acting reliever inhalers and long-term maintenance or preventer inhalers. It helps to monitor whether a medication is being taken in the appropriate manner to maximize effectiveness. For quick-acting relief inhalers, the sensor can track use changes over time. Increased use of a relief inhaler likely means that a person is experiencing more symptoms and may require treatment adjustments. Developed by NuvoAir, this sensor also monitors patients’ inhaling technique and provides real-time feedback with a colored light system. Technique data are sent to clinicians, who can provide additional training if needed. Such monitoring is medically important, as, in both COPD and asthma, appropriate and timely treatments are critical for minimizing the impact of symptoms on day-to-day life and for avoiding more serious health problems. Inhalers are often used to deliver treatments directly into the lungs.